Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

In 30 seconds

This phase 1b clinical trial evaluated the safety and efficacy of an accelerated 5-day inpatient venetoclax ramp-up in 40 patients with chronic lymphocytic leukemia (CLL). The study found that 97.5% of patients received obinutuzumab alongside venetoclax, with no clinical tumor lysis syndrome (TLS) observed. The overall response rate at 3 months was 78.0%.

Key findings

• None of the patients experienced clinical tumor lysis syndrome during the study.
• One patient developed laboratory TLS, which resolved with supportive care.
• The overall response rate at 3 months was 78.0%.

Why it matters

The findings suggest that an accelerated venetoclax ramp-up may be a safe alternative for initiating treatment in select CLL patients, potentially improving patient management and outcomes in experienced centers.